When was Klotho Neurosciences founded?

Klotho Neurosciences was founded in 2024 and raised its 1st funding round 2 years after it was founded.

Where is Klotho Neurosciences located?

Klotho Neurosciences is headquartered in Omaha, United States.

Is Klotho Neurosciences a funded company?

Klotho Neurosciences is a funded company, having raised a total of $***** in its 1st and only funding round, a Post IPO round on Mar 02, 2026.

When was the latest funding round of Klotho Neurosciences?

Klotho Neurosciences' latest funding was a $***** Post IPO round on Mar 02, 2026, with participation from 0 investor. Its primary sector is Neurology. In United States, the Neurology sector has seen $3.67B in funding in 2026 to date.

Where does Klotho Neurosciences rank among its competitors?

Klotho Neurosciences ranks 103rd amongst 457 active competitors, of which 161 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Alchemab, which secured $34M in Jul, 2026.

Who are the top competitors of Klotho Neurosciences?

Klotho Neurosciences' top competitors include Denali Therapeutics, Fulcrum Therapeutics and Regenxbio. Among them, Alchemab secured the most recent funding round in July, 2026.

Klotho Neurosciences - 2026 Company Profile, Funding & Competitors

Klotho Neurosciences is a late stage company based in Omaha (United States), founded in 2024. It operates as a Developer of therapies for age-related cognitive and neurodegenerative disorders. Klotho Neurosciences has raised an undisclosed amount in funding. The company has 457 active competitors, including 161 funded and 80 that have exited. Its top competitors include companies like Denali Therapeutics, Fulcrum Therapeutics and Regenxbio.

Company Details

Developer of therapies for age-related cognitive and neurodegenerative disorders. It offers cell and gene therapies to introduce a human gene into the body in secreted form of Klotho, s-KL for for neurodegenerative diseases, such as ALS, Alzheimer’s and Parkinson’s diseases.

Website: klothoneuro.com
Phone Number: +1 **********

Key Metrics

Founded Year

2024

Location

Omaha, United States

Stage

Late Stage

Latest Funding Round

Post IPO, Mar 02, 2026, $*****

Ranked

103^rd among 457 active competitors

Investment & Acquisitions

Greenland Mines Corp & 1 more

Similar Companies

Denali Therapeutics & 567 more

View Klotho Neurosciences' full profile

Klotho Neurosciences has raised funding over 1 round.

Here is the list of recent funding rounds of Klotho Neurosciences:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 02, 2026	4890613	Post IPO	3203711	9472063	6503639	3006847

Access funding benchmarks and valuations. Sign up today!

View details of Klotho Neurosciences's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Klotho Neurosciences include Denali Therapeutics, Fulcrum Therapeutics and Regenxbio. Here is the list of Top 10 competitors of Klotho Neurosciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Denali Therapeutics 2015, San Francisco (United States), Public	Developer of therapies to treat neurodegenerative diseases	$347M	Foresite Capital, Baillie Gifford & 10 others	72/100
2nd	Fulcrum Therapeutics 2015, Cambridge (United States), Public	Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases	$115M	Foresite Capital, Google Ventures & 15 others	71/100
3rd	Regenxbio 2008, Rockville (United States), Public	Developer of AAV Gene Therapy for rare genetic diseases	$108M	Brookside Capital, Venrock & 15 others	67/100
4th	Annexon 2011, San Francisco (United States), Public	Developer of antibodies to treat complement-mediated neurodegenerative diseases	$256M	Redmile Group, Blackstone & 17 others	67/100
5th	Alector 2013, San Francisco (United States), Public	Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders	$215M	AbbVie, The Dementia Discovery Fund & 20 others	65/100
6th	MeiraGTx 2015, New York City (United States), Public	Developer of gene therapies for ocular and neurodegenerative diseases	-	Perceptive Advisors, ATW Partners & 6 others	65/100
7th	Alchemab 2019, London (United Kingdom), Series A	Developer of antibody therapeutics for treating oncology and neurodegenerative conditions	$149M	RA Capital Management, SV Health Investors ... & 14 others	65/100
8th	Mission Therapeutics 2011, Cambridge (United Kingdom), Series D	Developer of small molecule inhibitors targeting specific disease associated enzymes	$192M	Sofinnova Partners, Pfizer Venture Investments ... & 46 others	64/100
9th	D&D Pharmatech 2014, Seongnam-si (South Korea), Public	Developer of GLP-1-based therapeutics for metabolic disease treatment	$205M	Praxis Capital, Smile Gate Investment & 10 others	64/100
10th	US World Meds 2001, Louisville (United States), Series B	Developer of therapeutics for the treatment of multiple diseases	$149M	Athyrium Capital Management, CRG & 6 others	63/100
103rd	Klotho Neurosciences 2024, Omaha (United States), Late Stage	Developer of therapies for age-related cognitive and neurodegenerative disorders	-	-	44/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Klotho Neurosciences's competitors? Click here to see the top ones

Klotho Neurosciences has acquired 2 companies including Greenland Mines Corp and Sbsecurityholdings. Klotho Neurosciences has not made any investments as of now.

Here is the latest report on Klotho Neurosciences's sector: